High Hope INT'L Group Jiangsu Medicines and Health Products IMP & EXP CORP Ltd. and Nanjing Economic and Technological Development Zone carry out docking and exchange
On June 18, High Hope INT'L Group Jiangsu Medicines and Health Products IMP & EXP CORP Ltd. (hereinafter referred to as "High Hope Medicines") held a dedicated exchange meeting with the Nanjing Economic and Technological Development Zone (NJEDZ).
Ms. Wang Jiajia, Deputy General Manager of Xingang Biomedical Company (a subsidiary of NJEDZ), led a delegation to High Hope Medicines. The delegation included officials from the Investment Promotion and Operation Department, the Science and Technology Bureau of NJEDZ, and heads of four pharmaceutical companies. High Hope Medicines was represented by its leadership team and heads of relevant departments.
Ms. Wang Jiajia provided an overview of NJEDZ and its pharmaceutical enterprises. She noted that NJEDZ is actively building an innovation-driven industrial cluster, with biomedicine as a key focus. High Hope Medicines, she added, possesses extensive experience in the pharmaceutical industry, a global marketing network covering major markets worldwide, and a professional international operations team. She expressed the hope that this meeting would serve as an opportunity to facilitate connections between NJEDZ-based companies and High Hope Medicines, deepen collaboration in "going global" and expanding into Belt and Road markets, and ultimately help enterprises improve quality and efficiency while accelerating transformation and upgrading.
The heads of the four visiting companies—Nanjing Ruibeixi Bio, Yilanbei Bio, Renmai Bio, and Yiweijianhua Bio—introduced their development histories, core products, and market strategies. They highlighted their respective technological strengths in areas such as magnetic nanomaterials, in vitro diagnostic (IVD) equipment, specialized detection reagents, and precision exosome diagnostics and therapeutics. They also discussed potential areas of cooperation and alignment with High Hope Medicines.
In response, High Hope Medicines detailed its own history, strategic planning, and main business segments. As a subsidiary of the Soho Holding Group specializing in pharmaceuticals and medical products, the company is working to share resources and channel advantages, and to build a convenient platform with service support for partner enterprises looking to expand into overseas markets. This special exchange represents a key step in integrating resources and pursuing synergistic development. High Hope Medicines acknowledged the innovative vitality and cutting-edge technologies emerging from NJEDZ’s biomedical sector, which it can learn from. The company expressed its ambition to serve as a solid bridge for NJEDZ-based enterprises to go global, offering customized overseas marketing solutions with a focus on Belt and Road markets such as Central Asia, Africa, and South America. The goal is to accelerate technology transfer, increase market share, and enhance the international competitiveness of NJEDZ’s biomedical industry.
The discussions were practical, in-depth, and conducted in a warm and constructive atmosphere. Both sides agreed that the exchange had laid a strong foundation for deeper cooperation. Going forward, they plan to establish a regular coordination mechanism, conduct on-site research at respective enterprises, develop a list of concrete cooperation projects, and facilitate precise matching of advantageous resources. The aim is to achieve tangible progress in product exports and technology transfer as soon as possible, jointly injecting new momentum into the high-quality development and global footprint of the biomedical industry.